Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity

Seminars in Oncology

Volumn 18, Issue 1 SUPPL. 3, 1991, Pages 49-55

  Gandara, David R ^a,b,c   Perez, Edith A ^a,b,c   Wiebe, Valerie ^a,b,c   De Gregorio, Michael W ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIETHYLDITHIOCARBAMIC ACID; ETOPOSIDE;

ANIMAL EXPERIMENT; BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER; DRUG TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; NEUROPATHY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; RAT; REVIEW;

AMIFOSTINE; ANTICONVULSANTS; CISPLATIN; CORTICOTROPIN; DITIOCARB; HUMAN; KIDNEY DISEASES; METABOLIC DETOXICATION, DRUG; NEOPLASMS; PEPTIDE FRAGMENTS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0025857621     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Evaluation of cisplatin dose intensity: Current status and future prospects
2. High-dose cisplatin in hypertonic saline
3. Cisplatin dose intensity in non-small cell lung cancer: Phase II results of a day 1 and 8 high dose regimen
4. Ototoxicity of low- and moderate-dose cisplatin
5. Cisplatin neuropathy: Clinical, electrophysiologic, morphologic, and toxicologic studies
6. Toxic side effects of cis-dichlorodiammineplatinum (II) in man
7. High-dose cisplatin in patients with advanced malignancy
8. High-dose cisplatin in metastatic melanoma: Comparison of two schedules
9. High-dose cisplatin in hypertonic saline: Reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group (NCOG) pilot study in non-small cell lung cancer
10. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties
11. Uptake of WR-2721 derivatives by cells in culture Identification of the transported form of the drug
12. Pharmacokinetics of WR-2721
13. Toxicity of WR-2721 administered in single and multiple doses
14. Phase I/II trials of WR-2721 and cisplatin
15. Cisplatin neuropathy: Risk factors, prognosis, and protection by WR-2721
16. WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma
17. The role of WR-2721 in the reduction of combined cisplatin and cyclophosphamide toxicity
18. Selective protection against cis-diamminedichloroplatinum (II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate
19. Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum (II)-induced cytotoxicity, DNA cross-linking, and glutamyl transpeptidase inhibition
20. Metabolism of disulfiram and diethyldithiocarbamate in rats with demonstration of an in vivo ethanol-induced inhibition of the glucuronic acid conjugation of the thiol
21. Phase I pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin
22. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: Preliminary pharmacologic observations
23. High dose carboplatin with diethyldithiocarbamate chemoprotector in the treatment of women with relapsed ovarian cancer
24. Modification of bone marrow toxicity of cis-diamminedichloroplatinum (II) in mice by diethyldithiocarbamate
25. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck
26. Phase I trial of high dose cisplatin plus diethyldithiocarbamate rescue: Toxicity profile compared to patients receiving high dose cisplatin alone
27. A phase I trial of diethyldithiocarbamate (DDTC) as a modifier of cisplatin (CP) toxicity
28. Diethyldithiocarbamate and cisplatinum toxicity
29. Assessment of cisplatin neuropathy by dynamic posturography
30. Efficacy of the neuropeptide ORG-2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats
31. Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer